

Contents

Author biographies	vii
1 Introduction and background biology	1
Introduction	1
Epidemiology	1
HER2 primary structure	2
Signal transduction through receptor tyrosine kinases	3
Receptor tyrosine kinases: site of therapeutic intervention	5
Signaling through HER-receptor family dimers leads to the activation of downstream cascades	5
The immune system and response to HER2-targeted treatment	9
Conclusions	10
References	10
2 HER2 testing	15
Introduction	15
Pre-analytic phase: sample handling	16
Analytic phase: HER2 testing methodologies	17
Post-analytic phase: screening and interpretation	18
Alternate HER2 testing methodologies	25
References	26
3 HER2-positive breast cancer: neoadjuvant and adjuvant therapy	29
Neoadjuvant therapy	29
Adjuvant therapy	33
Other anti-HER2 agents in the adjuvant setting	42
Current therapy standards for HER2-positive early breast cancer	44
Future directions and ongoing trials	44
References	46

4	HER2-positive metastatic breast cancer: first-line treatment	51
	Introduction	51
	Trastuzumab-based therapy	51
	Pertuzumab	55
	Other first-line anti-HER2 combination strategies	59
	Ongoing first-line studies	60
	HER2/hormone receptor co-positive tumors	60
	Conclusions	63
	References	65
5	HER2-positive metastatic breast cancer: second-line treatment	71
	Introduction	71
	Trastuzumab emtansine	72
	Lapatinib in the metastatic setting	80
	Trastuzumab-lapatinib combination therapy	82
	Conclusions	82
	References	83
6	Emerging targeted agents for HER2-positive breast cancer	87
	Challenges and unmet needs	87
	Novel HER2 tyrosine kinase inhibitors	89
	PI3K/Akt/mTOR inhibition	93
	Other signaling pathways	98
	Boosting immunological response to HER2 blockade	100
	Vascular endothelial growth factor inhibition	102
	Conclusions	105
	References	105

Handbook of HER2-Targeted Agents in Breast Cancer

Alvarez, R.H.; Cortés, J.; Falzon, M.; Gandy, M.; Gianni, L.;
Harbeck, N.; Piccart, M.

2016, XI, 110 p. 17 illus., 16 illus. in color., Softcover

ISBN: 978-3-319-28214-5